Also, a phase I clinical trial with 29 patients with advanced malignant melanoma showed an increase of 11.1 weeks in the median progression-free survival (PFS) upon treatment with the monoclonal anti-TGF-β antibody fresolimumab (GC1008). This evidence concerns the gene TGFB1 and melanoma.